As of 14 Oct 2026, Granite Bio has raised $100M across 2 verified rounds on record; latest: $70 million Series B led by Forbion and Sanofi Ventures, announced 24 Apr 2025.
Granitebio is a biotechnology company developing innovative therapies focusing on inflammatory, autoimmune, and fibrotic diseases with first-in-class antibodies.
1 source
Added by hand 2026-10-14 (big-round queue): Granite Bio's own release of 24 Apr 2025 states $100 million on emerging from stealth as a pair of financings, a $30 million Series A and a $70 million Series B, both announced that day; this row is the $70 million Series B, led by Forbion and Sanofi Ventures. The other part is its own row.
1 source
Added by hand 2026-10-14 (big-round queue): Granite Bio's own release of 24 Apr 2025 states $100 million on emerging from stealth as a pair of financings, a $30 million Series A and a $70 million Series B, both announced that day; this row is the $30 million Series A, led by Versant Ventures and Novartis Venture Fund. The other part is its own row.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $70M | 2025-04-24 | Forbion, Sanofi Ventures | No recent discussion |
1 source [ VERIFIED ] read against its primary page Added by hand 2026-10-14 (big-round queue): Granite Bio's own release of 24 Apr 2025 states $100 million on emerging from stealth as a pair of financings, a $30 million Series A and a $70 million Series B, both announced that day; this row is the $70 million Series B, led by Forbion and Sanofi Ventures. The other part is its own row. | ||||
| Series A [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $30M | 2025-04-24 | Versant Ventures, Novartis | No recent discussion |
1 source [ VERIFIED ] read against its primary page Added by hand 2026-10-14 (big-round queue): Granite Bio's own release of 24 Apr 2025 states $100 million on emerging from stealth as a pair of financings, a $30 million Series A and a $70 million Series B, both announced that day; this row is the $30 million Series A, led by Versant Ventures and Novartis Venture Fund. The other part is its own row. [ BUILT WITH ]·[ SEARCH ]found by Firecrawl search·[ SCRAPE ]1 page read: granitebio.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against its page with Firecrawl·[ BRANDING ]logo and colour from the homepage | ||||